Last updated: 11/03/2018 10:56:58
Evaluate safety and immunogenicity of GSK Bio's influenza vaccine GSK576389A after repeated vaccination in elderly adults
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: Reactogenicity and immunogenicity of GSK Biologicals' influenza vaccine GSK576389A in elderly adults (≥67 years) previously vaccinated with the same candidate vaccine. Fluarix™ will be used as reference.
Trial description: Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after repeated vaccine administration. In this study, the subjects previously enrolled in study 107973 will receive a dose with the 2007-2008 season's formulations of Fluarix or GSK576389A. Only subjects who were previously enrolled in study 107973 (NCT00386113) are eligible for participation in this study.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
Number of subjects reporting any and grade 3 solicited local symptoms
Timeframe: During a 7-day follow-up period after vaccination
Duration of solicited local symptoms
Timeframe: During a 7-day follow-up period after vaccination
Number of subjects reporting any, grade 3 and related solicited general symptoms
Timeframe: During a 7-day follow-up period after vaccination
Duration of solicited general symptoms
Timeframe: During a 7-day follow-up period after vaccination
Number of subjects reporting any, grade 3 and related unsolicited adverse events (AEs)
Timeframe: During a 21-day follow-up period after vaccination
Number of subjects reporting any, grade 3 and related medically significant conditions (MSCs)
Timeframe: During a 21-day follow-up period after vaccination
Number of subjects reporting any and related serious adverse events (SAEs)
Timeframe: Throughout the entire study (up to Day 21)
Secondary outcomes:
Serum Haemagglutination Inhibition (HI) antibody titers against each of the three vaccine strains
Timeframe: At Days 0 and 21
Number of subjects seropositive for HI antibodies against each of the three vaccine strains
Timeframe: At Days 0 and 21
Number of subjects seroconverted for HI antibodies against each of the three vaccine strains
Timeframe: At Day 21
Seroconversion Factors (SCFs) for HI antibodies against each of the three vaccine strains
Timeframe: At Day 21
Number of subjects seroprotected for HI antibodies against each of the three vaccine strains
Timeframe: At Days 0 and 21
Number of cytokine-positive Cluster of Differentiation 4 (CD4) T lymphocytes per million T lymphocytes for each of the three vaccine strains
Timeframe: At Days 0 and 21
Number of cytokine-positive Cluster of Differentiation 8 (CD8) T lymphocytes per million T lymphocytes for each of the three vaccine strains
Timeframe: At Days 0 and 21
Interventions:
Biological/vaccine: GSK Biologicals’ influenza vaccine GSK576389A
Biological/vaccine: Fluarix™
Enrollment:
68
Observational study model:
Not applicable
Primary completion date:
2007-12-12
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Influenza
Product
GSK576389A
Collaborators
Not applicable
Study date(s)
October 2007 to December 2007
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
67+ years
Accepts healthy volunteers
Yes
- Subjects who were previously vaccinated with GlaxoSmithKline Biologicals Fluarix™ or GSK576389A vaccines in the 107973 study (NCT00386113).
- Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days prior to vaccination, or planned use during the study period.
- Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study.
Inclusion and exclusion criteria
Inclusion criteria:
- Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
- A male or female aged >= 67 years at the time of re-vaccination.
- Written informed consent obtained from the subject.
- Free of an acute aggravation of the health status as established by clinical evaluation (medical history and medical history directed examination) before entering into the study.
Subjects who were previously vaccinated with GlaxoSmithKline Biologicals Fluarix™ or GSK576389A vaccines in the 107973 study (NCT00386113).
Exclusion criteria:
- Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study.
- Planned administration of a vaccine not foreseen by the study protocol up to 21 days after vaccination.
- Confirmed influenza infection since the date of previous vaccination.
- Planned administration of an influenza vaccine other than the study vaccines during the entire study period.
- Vaccination against influenza since January 2007 with the Northern Hemisphere 2007/2008 influenza vaccine or 2006/2007 influenza vaccine.
- Administration of more than 14 days of immunosuppressants or other immune-modifying drugs within six months prior to the administration of the study vaccine.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- History of hypersensitivity to a previous dose of influenza vaccine.
- History of allergy or reactions likely to be exacerbated by any component of the vaccine(s).
- Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by clinical evaluation (medical history and medical history directed physical examination) or pre-existing laboratory screening tests.
- Acute disease at the time of enrolment.
- Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the study vaccine or planned administration during the study.
- Any medical conditions in which intramuscular injections are contraindicated.
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days prior to vaccination, or planned use during the study period.
Trial location(s)
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2007-12-12
Actual study completion date
2007-12-12
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website